MGX · NASDAQ
Metagenomi Therapeutics (MGX) Stock Price & Fundamentals
Metagenomi Therapeutics (MGX) closed at $199.62 on Oct 9, 2026, down 0.91% from the previous close of $201.45.
Share price, past year
1Y +4.75%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $199.62 |
| Sep 30, 2026 | $198.98 |
| Aug 31, 2026 | $208.41 |
| Jul 31, 2026 | $203.55 |
| Jun 30, 2026 | $209.94 |
| May 29, 2026 | $211.78 |
| Apr 30, 2026 | $212.75 |
| Mar 31, 2026 | $205.41 |
| Feb 27, 2026 | $201.63 |
| Jan 30, 2026 | $211.38 |
| Dec 31, 2025 | $210.42 |
| Nov 28, 2025 | $210.05 |
| Oct 31, 2025 | $198.80 |
Key statistics
- Market cap
- $7.54B
- P/E (TTM)
- —
- EPS (TTM)
- −$2.48
- Revenue (TTM)
- $22.33M
- Net income (TTM)
- −$93.46M
- Shares outstanding
- 37.8M
- Dividend yield
- —
- 52-week range
- $189.14 – $223.22
Metagenomi Therapeutics's market cap is $7.54B, based on a share price of $199.62 and 37.8M shares outstanding as of Jun 30, 2026.
Financials
Metagenomi Therapeutics reported revenue of $25.21M for fiscal 2025, down 51.79% from fiscal 2024.
Metagenomi Therapeutics reported a net loss of $87.87M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $25.21M | −51.8% | −$87.87M | −348.5% | −$2.36 | −$89.47M |
| FY2024ended Dec 31, 2024 | $52.30M | +16.8% | −$78.06M | −149.3% | −$2.36 | −$112.19M |
| FY2023ended Dec 31, 2023 | $44.76M | — | −$68.26M | −152.5% | −$20.05 | −$101.22M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q1 FY2026ended Mar 31, 2026 | $1.25M | −$23.06M | −$0.61 |
| Q4 FY2025ended Dec 31, 2025 | $3.91M | −$22.53M | −$0.59 |
| Q3 FY2025ended Sep 30, 2025 | $8.66M | −$20.39M | −$0.55 |
| Q2 FY2025ended Jun 30, 2025 | $8.51M | −$19.91M | −$0.54 |
| Q1 FY2025ended Mar 31, 2025 | $4.13M | −$25.04M | −$0.68 |
| Q4 FY2024ended Dec 31, 2024 | $9.61M | −$23.40M | −$0.37 |
| Q3 FY2024ended Sep 30, 2024 | $11.51M | −$18.77M | −$0.51 |
| Q2 FY2024ended Jun 30, 2024 | $20.01M | — | — |
Company profile
- Name
- Metagenomi Therapeutics, Inc.
- Ticker
- MGX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 5959 Horton Street, 7th Floor, Emeryville, CA 94608
- Fiscal year ends
- December
- SEC CIK
- 0001785279
Recent SEC filings
- Sep 22, 2026
- Aug 10, 2026
- Aug 10, 2026
- Jun 10, 2026
- May 11, 2026
- May 11, 2026
- Mar 5, 2026
- Mar 5, 2026
Frequently asked questions
What is Metagenomi Therapeutics's stock price?
Metagenomi Therapeutics (MGX) closed at $199.62 on Oct 9, 2026, down 0.91% from the previous close of $201.45.
What is Metagenomi Therapeutics's market cap?
Metagenomi Therapeutics's market cap is $7.54B, based on a share price of $199.62 and 37.8M shares outstanding as of Jun 30, 2026.
How much revenue does Metagenomi Therapeutics make?
Metagenomi Therapeutics reported revenue of $25.21M for fiscal 2025, down 51.79% from fiscal 2024.
Does Metagenomi Therapeutics pay a dividend?
Metagenomi Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Metagenomi Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures